Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK3745417 in relapsed/refractory AML or HR-MDS
NCT05424380Phase 1Terminated
- Sponsor
- GSK
- Start
- Sep 2022
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label trial of GSK3745417 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (2 arms), sponsored by GSK. Primary endpoints: Treatment-emergent Adverse Events up to 49 weeks, Dose Limiting Toxicities up to 28 days and 2 more. Started Sep 2022; status: terminated.
02
Drugs
GSK3745417
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT05424380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05424380.